Loading...
XWAR
PHR
Market cap10mUSD
Jul 28, Last price  
3.54PLN
1D
0.00%
1Q
-19.55%
Jan 2017
-79.95%
IPO
-85.41%
Name

Pharmena SA

Chart & Performance

D1W1MN
XWAR:PHR chart
No data to show
P/E
1.36
P/S
4.01
EPS
2.60
Div Yield, %
24.01%
Shrs. gr., 5y
4.84%
Rev. gr., 5y
-5.48%
Revenues
10m
-48.29%
3,809,8466,379,5497,704,3868,778,3819,130,00014,138,00014,129,00017,473,00015,914,00012,511,00013,040,00011,099,0009,933,00015,213,00019,022,0009,837,000
Net income
29m
P
611,360771,541123,730608,997-4,100,000-2,843,000-4,086,000-3,616,000-1,664,000-2,389,000-444,000-9,573,000-6,958,000-4,639,000-1,616,00028,941,000
CFO
33m
+1,715.94%
000666,906-4,054,000-3,836,000-5,751,000-4,175,000-950,000619,0003,613,000-13,146,000-2,243,000-3,225,0001,819,00033,032,000
Dividend
Apr 09, 20240.85 PLN/sh
Earnings
Aug 25, 2025

Profile

Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including skin, hair, and nail care products, as well as dietary supplement for atherosclerosis prophylaxis. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names. The company is developing 1-MNA, an anti-atherosclerosis drug which is under phase II clinical trial. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. is a subsidiary of Pelion S.A.
IPO date
Aug 25, 2008
Employees
24
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
9,837
-48.29%
19,022
25.04%
Cost of revenue
11,869
19,382
Unusual Expense (Income)
NOPBT
(2,032)
(360)
NOPBT Margin
Operating Taxes
5,908
204
Tax Rate
NOPAT
(7,940)
(564)
Net income
28,941
-1,890.90%
(1,616)
-65.16%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
69
316
Long-term debt
295
704
Deferred revenue
Other long-term liabilities
21
2,207
Net debt
(21,873)
(45,027)
Cash flow
Cash from operating activities
33,032
1,819
CAPEX
(314)
(226)
Cash from investing activities
(3,132)
(219)
Cash from financing activities
(9,261)
(1,466)
FCF
(14,383)
3,342
Balance
Cash
22,237
1,592
Long term investments
44,455
Excess cash
21,745
45,096
Stockholders' equity
(21,951)
(49,909)
Invested Capital
44,381
45,660
ROIC
ROCE
8.47%
EV
Common stock shares outstanding
11,138
11,138
Price
7.10
26.79%
5.60
-29.20%
Market cap
79,078
26.79%
62,371
-29.03%
EV
56,910
17,042
EBITDA
(1,707)
201
EV/EBITDA
84.79
Interest
371
722
Interest/NOPBT